GINA CAIN: Open Payments
NPI 1497429807 · TOMS RIVER, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$646 in 32 payments from 8 companies in 2025. Trend: 2023 $518 · 2024 $228 · 2025 $646
Food & beverage: $548Education: $98
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $178 |
| ABBVIE INC. | 15 | $160 |
| E.R. Squibb & Sons, L.L.C. | 2 | $143 |
| Alkermes, Inc. | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: VRAYLAR, COBENFY, AUSTEDO XR, ARISTADA, FANAPT, REXULTI, INGREZZA, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
